Valuation: GENFIT

Market Cap 705M 824M 659M 604M 1.14B 78.85B 1.16B 7.81B 3.04B 39.43B 3.09B 3.02B 131B P/E 2026 *
36.4x
P/E 2027 * 93.6x
Enterprise Value 654M 764M 611M 560M 1.05B 73.13B 1.07B 7.25B 2.82B 36.57B 2.87B 2.81B 122B EV / Sales 2026 *
6.53x
EV / Sales 2027 * 5.15x
Free-Float
86.89%
Yield 2026 *
-
Yield 2027 * -
1 day-2.10%
1 week+7.20%
Current month-4.11%
1 month+9.20%
3 months+66.27%
6 months+70.21%
Current year+174.51%
1 week 12.94
Extreme 12.94
14.74
1 month 12.6
Extreme 12.6
15.4
Current year 5.06
Extreme 5.055
15.4
1 year 3.58
Extreme 3.578
15.4
3 years 3.3
Extreme 3.305
15.4
5 years 2.96
Extreme 2.964
15.4
10 years 2.96
Extreme 2.964
21.74
Manager TitleAgeSince
Chief Executive Officer 58 2019-09-15
Director of Finance/CFO 52 2021-04-21
Chief Tech/Sci/R&D Officer - 2025-11-26
Director TitleAgeSince
Chairman 70 2017-06-15
Director/Board Member 54 1999-09-14
Director/Board Member 58 2017-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-2.10%+7.20% - - 840M
+1.14%+3.46%+4.57%+24.14% 50.5B
-1.36%+3.15%+479.46%+614.84% 46.01B
-2.04%+2.82%+18.13%+91.23% 42.85B
+2.72%+5.93%+33.12%+19.66% 41.03B
0.00%-3.91%+17.87%+47.98% 32.02B
+0.72%+2.62%+32.57%+145.37% 16.98B
-1.85%-0.25% - - 17.05B
+3.06%+4.63%+7.40%+35.00% 14.3B
+0.50%+2.49%+83.90%+46.53% 13.84B
Average +0.08%+2.01%+84.63%+128.09% 30.51B
Weighted average by Cap. +0.18%+2.37%+104.14%+152.88%

Financials

2026 *2027 *
Net sales 100M 117M 93.65M 85.84M 161M 11.2B 165M 1.11B 433M 5.6B 439M 430M 18.61B 124M 145M 116M 106M 200M 13.87B 204M 1.37B 535M 6.93B 544M 532M 23.04B
Net income 22.88M 26.71M 21.38M 19.6M 36.82M 2.56B 37.57M 253M 98.76M 1.28B 100M 98.12M 4.25B 6.8M 7.94M 6.36M 5.83M 10.94M 760M 11.17M 75.31M 29.35M 380M 29.81M 29.16M 1.26B
Net Debt -51.12M -59.69M -47.78M -43.79M -82.27M -5.71B -83.94M -566M -221M -2.86B -224M -219M -9.49B -66.17M -77.27M -61.85M -56.69M -107M -7.4B -109M -733M -286M -3.7B -290M -284M -12.29B
Logo GENFIT
GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades. The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).
Employees
161
Date Price Change Volume
26-08-20 €14.00 -2.10% 7,373
26-08-19 €14.30 +4.69% 10,242
26-08-18 €13.66 -1.44% 2,077
26-08-17 €13.86 +7.11% 11,667
26-08-14 €12.94 -2.56% 7,281
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.40EUR
Average target price
15.90EUR
Spread / Average Target
+10.42%

Quarterly revenue - Rate of surprise